ASA’s Task Force: Stop taking GLP-1 medications for diabetes and weight loss before elective surgery
With the growing popularity of medications like Ozempic (semaglutide), Trulicity (dulaglutide) and other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes and weight loss, the American Society of Anesthesiologists (ASA) has suggested withholding the medication before elective surgery to reduce the risk of complications associated with anaesthesia in adults and children.
GLP-1 agonists are approved by the FDA to treat type 2 diabetes and reduce the risk of cardiovascular disease. The medications are also used for weight loss, as they delay gastric (stomach) emptying, decreasing hunger and reducing how much people eat.
“While there is currently a lack of scientific data on how GLP-1 receptor agonists affect patients having surgery and interact with anaesthesia, we’ve received anecdotal reports that the delay in stomach emptying could be associated with an increased risk of regurgitation and aspiration of food into the airways and lungs during general anaesthesia and deep sedation,” said ASA President, Dr Michael Champeau. “These complications can be serious, so we are providing guidance on when GLP-1 agonists should be stopped in advance of an elective procedure. I would like to thank Drs Karen Domino, chair of the ASA’s Committee on Practice Parameters (CPP) and Girish Joshi, vice-chair of the CPP, as well as ASA’s Task Force on Preoperative Fasting for their commitment to patient safety in developing this guidance.”
Initial reports have found that patients who have experienced GI side effects, such as nausea or vomiting, while taking GLP-1 agonists were more likely to have increased residual gastric contents. Children experience GI side effects at a similar rate to adults.
ASA’s Task Force on Preoperative Fasting suggests the following for patients taking GLP-1 agonists for type 2 diabetes or weight loss who are having elective procedures. It is also calling for further research to be done regarding GLP-1 agonist medications and anaesthesia.
Day or week prior to the procedure:
Hold GLP-1 agonists on the day of the procedure/surgery for patients who take the medication daily.
Hold GLP-1 agonists a week prior to the procedure/surgery for patients who take the medication weekly.
Consider consulting with an endocrinologist for guidance in patients who are taking GLP-1 agonists for diabetes management to help control their condition and prevent hyperglycaemia.
Day of the procedure:
Consider delaying the procedure if the patient is experiencing GI symptoms such as severe nausea/vomiting/retching, abdominal bloating or abdominal pain and discuss the concerns of potential risk of regurgitation and aspiration with the proceduralist or surgeon and the patient.
Continue with the procedure if the patient has no GI symptoms and the GLP-1 agonist medications have been held as advised.
If the patient has no GI symptoms, but the GLP-1 agonist medications were not held, use precautions based on the assumption the patient has a “full stomach” or consider using ultrasound to evaluate the stomach contents. If the stomach is empty, proceed as usual. If the stomach is full or if the gastric ultrasound is inconclusive or not possible, consider delaying the procedure or proceed using full stomach precautions. Discuss the potential risk of regurgitation and aspiration of gastric contents with the proceduralist or surgeon and the patient.
Full stomach precautions also should be used in patients who need urgent or emergency surgery.